Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tazemetostat - Ipsen

Next Previous
Drug Profile

Tazemetostat - Ipsen

Alternative Names: E-7438; EPZ-6438; EZ-438; IPN-60200; Tazemetostat hydrobromide - Ipsen; Tazverik

Latest Information Update: 04 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Epizyme
  • Developer Eisai Co Ltd; Epizyme; Genentech; HUTCHMED; Ipsen; National Cancer Institute (USA); Pfizer
  • Class Amines; Antineoplastics; Benzamides; Biphenyl compounds; Dihydropyridines; Morpholines; Small molecules
  • Mechanism of Action Enhancer of zeste homolog 2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chordoma; Follicular lymphoma; Soft tissue sarcoma; Diffuse large B cell lymphoma; Rhabdoid tumour; Mesothelioma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Follicular lymphoma; Sarcoma
  • Registered Non-Hodgkin's lymphoma
  • Phase II CNS cancer; Diffuse large B cell lymphoma; Endometrial cancer; Histiocytosis; Lymphoma; Mesothelioma; Ovarian cancer; Prostate cancer; Solid tumours; Synovial sarcoma
  • Phase I/II Bladder cancer; Non-small cell lung cancer
  • No development reported Rhabdoid tumour
  • Discontinued Mantle-cell lymphoma

Most Recent Events

  • 04 Apr 2025 Launched for Follicular lymphoma (Second-line therapy or greater) in China (PO)
  • 21 Mar 2025 Registered for Follicular lymphoma (Second-line therapy or greater) in China (PO)
  • 31 Dec 2024 National Cancer Institute and Children's Oncology Group completes a phase II NCI-COG Paediatric MATCH trial in Solid tumours, Non-Hodgkin lymphoma (Second-line therapy or greater, Late-stage disease, In infants, In children, In adolescents, In adults) in USA and Puerto Rico (PO) due to scheduled interim monitoring (NCT03213665)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top